The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”
An article from
Dive Brief
//
Obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk sues Eli Lilly over "maliciously and deceptively false" GLP-1 ads
Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug
Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign
Novo escalates Lilly false advertising suit with planned bid to halt comparative ads
Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
